Exclusive: After winning legal battle, former PhaseBio investor finds US buyer for its PhIII drug to reverse Brilinta
2023-05-11
专利侵权并购引进/卖出优先审批
Having wrangled control of a blood thinner reversal agent, SFJ Pharma has found a buyer for the drug.
SERB Pharmaceuticals, a specialty pharma that vastly expanded its portfolio through several mergers in recent years, is picking up US rights to bentracimab, which is designed to reverse the anti-coagulating effects of AstraZeneca’s Brilinta (ticagrelor). PhaseBio originally licensed the drug from AstraZeneca’s former biologics arm MedImmune, and SFJ hopped aboard midway with development funding. But when PhaseBio sounded an alarm bell regarding the company’s finances, SFJ demanded rights to the drug — and won the legal battle earlier this year. In the process, PhaseBio also filed for
Chapter 11 bankruptcy
.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
-靶点
-
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。